Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Buy
64
TCRT Quote, Financials, Valuation and Earnings
Last price:
$4.37
Seasonality move
:
10.25%
Day range:
$3.90 - $4.42
52-week range:
$1.31 - $6.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1,174.04x
P/B ratio:
3.18x
Volume:
126K
Avg. volume:
54.3K
1-year change:
79.73%
Market cap:
$8.9M
Revenue:
$10K
EPS (TTM):
-$2.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TCRT
Alaunos Therapeutics, Inc.
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TCRT
Alaunos Therapeutics, Inc.
|
$3.99 | -- | $8.9M | -- | $0.00 | 0% | 1,174.04x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.81 | $0.85 | $228.1M | 3.04x | $0.80 | 0% | 3.52x |
|
NNVC
NanoViricides, Inc.
|
$1.37 | $7.00 | $24.7M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.99 | $2.00 | $810.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.22 | $7.00 | $7.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TCRT
Alaunos Therapeutics, Inc.
|
-- | 2.827 | -- | 2.10x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TCRT
Alaunos Therapeutics, Inc.
|
-- | -$1.2M | -163.5% | -163.5% | -54600% | -$941K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Alaunos Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns TCRT or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -53650% compared to Alaunos Therapeutics, Inc.'s net margin of -255.85%. Alaunos Therapeutics, Inc.'s return on equity of -163.5% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital TCRTAlaunos Therapeutics, Inc.-- -$0.55 $2.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About TCRT or NBY?
Alaunos Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 5050.37%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -53.04%. Given that Alaunos Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Alaunos Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCRTAlaunos Therapeutics, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is TCRT or NBY More Risky?
Alaunos Therapeutics, Inc. has a beta of -1.292, which suggesting that the stock is 229.154% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock TCRT or NBY?
Alaunos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Alaunos Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRT or NBY?
Alaunos Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Alaunos Therapeutics, Inc.'s net income of -$1.2M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Alaunos Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alaunos Therapeutics, Inc. is 1,174.04x versus 3.52x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRTAlaunos Therapeutics, Inc.1,174.04x -- -- -$1.2M NBYNovaBay Pharmaceuticals, Inc.3.52x 3.04x $521K -$1.3M
-
Which has Higher Returns TCRT or NNVC?
NanoViricides, Inc. has a net margin of -53650% compared to Alaunos Therapeutics, Inc.'s net margin of --. Alaunos Therapeutics, Inc.'s return on equity of -163.5% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital TCRTAlaunos Therapeutics, Inc.-- -$0.55 $2.8M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About TCRT or NNVC?
Alaunos Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 5050.37%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 410.95%. Given that Alaunos Therapeutics, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Alaunos Therapeutics, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCRTAlaunos Therapeutics, Inc.0 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is TCRT or NNVC More Risky?
Alaunos Therapeutics, Inc. has a beta of -1.292, which suggesting that the stock is 229.154% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock TCRT or NNVC?
Alaunos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alaunos Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRT or NNVC?
Alaunos Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Alaunos Therapeutics, Inc.'s net income of -$1.2M is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Alaunos Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alaunos Therapeutics, Inc. is 1,174.04x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRTAlaunos Therapeutics, Inc.1,174.04x -- -- -$1.2M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns TCRT or OGEN?
Oragenics, Inc. has a net margin of -53650% compared to Alaunos Therapeutics, Inc.'s net margin of --. Alaunos Therapeutics, Inc.'s return on equity of -163.5% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital TCRTAlaunos Therapeutics, Inc.-- -$0.55 $2.8M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About TCRT or OGEN?
Alaunos Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 5050.37%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 103.05%. Given that Alaunos Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Alaunos Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCRTAlaunos Therapeutics, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is TCRT or OGEN More Risky?
Alaunos Therapeutics, Inc. has a beta of -1.292, which suggesting that the stock is 229.154% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock TCRT or OGEN?
Alaunos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alaunos Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRT or OGEN?
Alaunos Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Alaunos Therapeutics, Inc.'s net income of -$1.2M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Alaunos Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alaunos Therapeutics, Inc. is 1,174.04x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRTAlaunos Therapeutics, Inc.1,174.04x -- -- -$1.2M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns TCRT or PTN?
Palatin Technologies has a net margin of -53650% compared to Alaunos Therapeutics, Inc.'s net margin of --. Alaunos Therapeutics, Inc.'s return on equity of -163.5% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TCRTAlaunos Therapeutics, Inc.-- -$0.55 $2.8M PTNPalatin Technologies-- -- -- -
What do Analysts Say About TCRT or PTN?
Alaunos Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 5050.37%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Alaunos Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Alaunos Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCRTAlaunos Therapeutics, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is TCRT or PTN More Risky?
Alaunos Therapeutics, Inc. has a beta of -1.292, which suggesting that the stock is 229.154% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock TCRT or PTN?
Alaunos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alaunos Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRT or PTN?
Alaunos Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Alaunos Therapeutics, Inc.'s net income of -$1.2M is higher than Palatin Technologies's net income of --. Notably, Alaunos Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alaunos Therapeutics, Inc. is 1,174.04x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRTAlaunos Therapeutics, Inc.1,174.04x -- -- -$1.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns TCRT or TOVX?
Theriva Biologics, Inc. has a net margin of -53650% compared to Alaunos Therapeutics, Inc.'s net margin of --. Alaunos Therapeutics, Inc.'s return on equity of -163.5% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital TCRTAlaunos Therapeutics, Inc.-- -$0.55 $2.8M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About TCRT or TOVX?
Alaunos Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 5050.37%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3039.01%. Given that Alaunos Therapeutics, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe Alaunos Therapeutics, Inc. is more attractive than Theriva Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCRTAlaunos Therapeutics, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is TCRT or TOVX More Risky?
Alaunos Therapeutics, Inc. has a beta of -1.292, which suggesting that the stock is 229.154% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock TCRT or TOVX?
Alaunos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alaunos Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRT or TOVX?
Alaunos Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Alaunos Therapeutics, Inc.'s net income of -$1.2M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Alaunos Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alaunos Therapeutics, Inc. is 1,174.04x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRTAlaunos Therapeutics, Inc.1,174.04x -- -- -$1.2M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
50
PLAB alert for Dec 10
Photronics, Inc. [PLAB] is up 45.35% over the past day.
Buy
60
OLMA alert for Dec 10
Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
